Read Full Post »

A 2024 case report published in Exploratory Research and Hypothesis in Medicine by a clinical team at Kyungpook National University Hospital (Daegu, South Korea) documented three individual patients—one with stage IV metastatic breast cancer, one with recurrent malignant melanoma, and one with castration-resistant prostate cancer—who independently self-administered veterinary-grade fenbendazole after their cancers continued to progress despite surgery, chemotherapy, immunotherapy, and hormonal therapy.

According to the authors, each patient went on to achieve complete or near-complete remission verified by imaging, and all remained disease-free during follow-up periods ranging from 11 months to 34 months, with no fenbendazole-related side effects reported.

Read Full Post »

Read Full Post »

Read Full Post »

Read Full Post »

Read Full Post »

Read Full Post »

Read Full Post »

A revolutionary cancer vaccine has shown astonishing success in clinical trials, targeting pancreatic and colorectal cancers—two of the most lethal and treatment-resistant forms. Developed by BioNTech and Genentech, the mRNA-based vaccine trains the body’s immune system to recognize and destroy cancer cells with remarkable precision.

In a Phase I trial, 84% of patients showed strong immune responses, and many have remained cancer-free for over 2 years post-treatment. The vaccine customizes its RNA code based on each patient’s tumor, marking a major step toward personalized oncology.

This breakthrough not only provides new hope for terminal cancer patients but also confirms the broader application of mRNA vaccine platforms beyond COVID-19. Experts believe this approach could soon extend to lung, liver, and even brain cancers.

Read Full Post »

Scientists at the University of New Mexico have developed a groundbreaking vaccine that targets the tau protein—a toxic buildup inside neurons widely believed to cause memory loss and cognitive decline in Alzheimer’s patients. Unlike current treatments that only slow symptoms, this vaccine activates the immune system to find and destroy tau tangles before they can do damage.

In preclinical trials, genetically engineered mice showed a dramatic reduction in tau deposits and preserved brain function longer than expected. With human trials on the horizon, researchers hope this could shift the fight against Alzheimer’s from reactive to preventive — a future where memory loss might be stopped before it starts.

Read Full Post »